FMP
Ginkgo Bioworks Holdings, Inc.
DNA
NYSE
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
10.22 USD
0.85 (8.32%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Jason Kelly Ph.D.
sector
Healthcare
industry
Biotechnology
exchange
NYSE
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
CIK
0001830214
ISIN
US37611X1000
CUSIP
37611X100
Address
27 Drydock Avenue
Phone
877 422 5362
Country
US
Employee
1,218
IPO Date
Apr 19, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
DNA Financial Summary
CIK
0001830214
Exchange
NYSE
Industry
Biotechnology
Sector
Healthcare
CUSIP
37611X100
ISIN
US37611X1000
Country
US
Price
10.22
Beta
1.1
Volume Avg.
1.18M
Market Cap
587.43M
Shares
-
52-Week
5.26-72.0
DCF
-7.93
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.79
P/B
-
Website
https://www.ginkgobioworks.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest DNA News
It looks like there's no news available.
